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Abstract We have microinjected constructs containing the 
murine IG II P3 promoter linked to different flanking sequences 
and a luciferase reporter gene into mouse pronuclei to establish 
transgenic lines of mice. The offspring was used as a source of 
embryonic fibroblast cultures and the effect of exogenous 
addition of glucocorticoids on transgene expression was ana-
lysed. It was found that both dexamethasone and hydrocortisone 
gave rise to a functional stimulation of the IGF II P3 promoter 
when the construct also contained other elements. This study 
demonstrates for the first time that there is an effect of 
glucocorticoids on the activation of an embryonic IGF II 
promoter, thus providing a molecular rationale for previous 
findings that glucocorticoids can under certain circumstances 
give rise to an increased transcriptional activity of the IGF II 
gene. 
© 1997 Federation of European Biochemical Societies. 
Key words: Insulin-like growth factor II; Glucocorticoid; 
Promoter 
1. Introduction 
The insulin like growth factor II is one of the key growth 
regulatory pep tide factors in mammalian embryogenesis [1]. 
Its expression is regulated at many levels in all vertebrates 
examined, including man [2]. For instance, gene imprinting 
usually inhibits transcription from the alíele inherited from 
the mother [3], translational control discriminates between 
mRNA with different leader exons [4-6] and the IGF II/Man-
nose-6-phosphate receptor acts as a scavenger for circulating 
IGF II [7]. IGF II levels in tissues and plasma are also influ-
enced by other hormones, by tissue type, by stage of develop-
ment and when neoplasia develops [8,9]. It has previously 
been suggested that IGF II transcription is under the control 
of glucocorticoids. Whereas some studies suggest that the IGF 
II expression is down-regulated by glucocorticoids [10-12], 
others suggest the contrary [13,14]. In all IGF II genes hith-
erto studied, existing data suggest the presence of different 
promoters. Moreover in higher mammals, the IGF II pro-
moters appear to fall into two categories, adult and embryonic 
[15-18]. 
The transcription of the IGF II gene is driven from three 
distinct promoters in the mouse. All three promoters are ex-
clusively active in embryonic life but their activities differ with 
respect to stage and tissue. In this study we have focused on 
the IGF II P3 promoter which is a major contributor of IGF 
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II transcripts in the mouse embryo [4]. In particular we aimed 
to find out if this promoter could be specifically activated by 
addition of glucocorticoids. This was studied by pronuclear 
injection transgenesis which was further developed into an in 
vitro system which provided us with a possibility to evaluate 
stably integrated constructs in reporter gene assays. 
It has previously been shown that the P3 promoter se-
quence alone linked to a reporter gene was relatively poorly 
active in transgenic mice. However when the P3 promoter was 
coupled with other enhancers from the IGF II/H19 locus it 
expressed at considerably higher levels [19]. In this study we 
therefore selected four different cis-acting elements for our 
construct: the H19 promoter, the H19 enhancer, the DMR1 
(5' differential methylated region) and the intergenic region 
(central conserved region, CCD). It has been shown that de-
letion of H19 enhancer severely impaired the expression of 
both the HI9 gene and the neighbouring IGF II gene [20]. 
In contrast, deletion of the HI9 coding region together with 
about 10 kb of 5' sequence from the maternal chromosome 
resulted in activation of the normally silent maternal IGF II 
alíele [21]. These observations are consistent with a model in 
which the H19 promoter activity limits this enhancers activity 
on eis IGF II promoters [22]. 
The DMR1 was chosen because there is indirect evidence 
that it might control IGF II gene activity. DMR1 lies about 
2 kb 5' to the transcriptional start site of exon 1 of the IGF II 
gene. This region was more highly methylated when paternally 
inherited [23-26], and methylation was known to be needed 
for the onset of IGF II expression in development [27]. DMRs 
have also been found in all imprinted genes to date [28]. 
Finally, the intergenic region (CCD) which is located between 
the IGF II and HI9 genes was chosen because it is a highly 
conserved sequence [29]. It is not associated with any novel 
transcriptional unit and it can act as a tissue specific enhancer 
of IGF II P3 in transgenic mice [19]. 
These elements were variously linked to the IGF II P3 
promoter and a luciferase reporter gene. The constructs 
were injected into pronuclei, and the offspring used for the 
production of embryonic fibroblast cultures, which could be 
used as an assay to examine the effect of glucocorticoids on 
the P3 promoter activity. Four out of five constructs tested 
were expressed in embryonic fibroblasts and in both cases, 
their expression was elevated 2-3-fold by glucocorticoid treat-
ment. 
2. Material and methods 
2.1. Transgenesis and breeding 
Transgene constructs (Fig. 1) and derivation of transgenic mouse 
lines were previously described [19]. The transgenic lines used in this 
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study were Oat (O construct), Hamish, Harry and Holly (H construct) 
Elvis (E construct), Azure, Ann and Archy (A construct) and Titus (T 
construct) selected as representatives of several lines made using each 
construct [19]. Transgenes were made and maintained on an Fl 
(C57BL/6 X CBA) genetic background and primary embryonic fibro-
blasts were made using embryos from mating a transgenic male with 
non-transgenic Fl females. Matings were timed by checking females 
for the presence of copulation plugs, with the day that a plug was 
detected assigned embryonic day E0.5. 
The presence of transgenes was detected by assaying luciferase ex-
pression in yolk sacks and placentas, dissected along with embryos 
used to make primary fibroblast cultures. The efficacy of using trans-
gene expression to follow transgene transmission had previously been 
tested extensively, and the methods used for assaying luciferase acti-
vity in homogenates of tissue samples were also detailed [19]. In the 
case of cultured fibroblasts, the cell monolayers were lysed directly 
using 0.5-1 ml 1 Xlysis buffer (Promega, UK), and lysates were trans-
ferred to micro fuge tubes and cleared by centrifugation at 2000 Xg for 
20 s. Ten ul of the supernatant was assayed directly for luciferase 
activity in a luminometer (Berthold model LB953 or Anthos model 
Lucy 1). 
2.2. Primary embryo fibroblasts 
On embryonic day E14.5, pregnant mice were dissected and the 
embryos, placentas and yolk sacks were collected. Parts of the pla-
centa and the yolk sack were used for luciferase determination. A 
relative light unit (RLU) value significantly above background (buffer 
only and non-transgenic samples gave approximately 60 RLUs where-
as transgenic placenta and yolk sack samples gave > 10000 RLUs) 
was taken as evidence for successful transmission and expression of 
the transgene. All embryos were numbered, humanely killed and their 
bodies (following removal of the head and abdominal organs) dis-
sected under sterile conditions in ice cold PBS into small lumps by 
scalpels. The lumps were then incubated in 0.25% trypsin for 5 min at 
room temperature. The supernatant was then transferred to a fresh 
tube containing equal amounts of alpha modified Eagle's medium 
(oe-MEM) supplemented with 10% serum. The cell suspension was 
spun twice and resuspended in a-MEM with 10% serum and then 
plated onto a 90 mm Petri dish. After 24 h the medium was changed 
and 24-48 h later the cells were trypsinised with 0.25% trypsin and the 
cultures split in 1:8-1:15 depending on the initial density. 
After one further round of subcultivation the cultures were exposed 
to 10~7 M hydrocortisone or 10~9-10~6 M dexamethasone. After 24 h 
the cells were rinsed with ice cold PBS, scraped off the dishes and 
transferred into tubes for luciferase activity measurement. A small 
aliquot was taken for protein determination by a Biorad protein as-
say. All RLU values were finally corrected for any differences in 
soluble protein content. 
In a separate set of experiments an expression vector containing the 
human glucocorticoid receptor gene was added (pRShGRa, [30]), to 
ensure a constitutive expression of the receptor in the cells. In these 
experiments, cells were plated and rinsed after 25 h. Fresh medium 
containing the plasmid was added and the cells was exposed for 48 h. 
After this period, the medium was changed and different concentra-
tions of dexamethasone or hydrocortisone were added as described in 
Tables 1 and 2. After 24 h exposure to the glucocorticoid containing 
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Fig. 1. The murine IGF II/H19 locus and transgene constructs (data 
from [21,22,25,26,28,36]). A genomic region (top, not drawn to 
scale) is depicted, showing the relative positions of IGF II and H19 
(open boxes), the 5' differentially methylated region (DMR), IGF II 
promoter 3 (P3), the central conserved domain (CCD, hatched box), 
and 3' enhancer region (filled boxes). Regions containing cytosine 
residues that are differently methylated on the two parental alíeles 
are marked (lollipops, note that each region contains multiple differ-
entially methylated residues). Transgene constructs O, A, H, T and 
E containing a firefly luciferase reporter gene (LUC) with different 
combinations of sequences from the IGF/H19 locus are also shown 
(bottom). 
medium the cells were rinsed in cold PBS, scraped off the plates and 
analysed as described above. 
2.3. Statistics 
All differences between means were analysed by the Student's 
paired i-test. The level of significance was set at 0.025. 
3. Results and discussion 
Five different constructs were injected into pronuclei 
(Fig. 1). The first and largest construct (O) contained the 
I G F II P3 promoter coupled to a luciferase (LUC) reporter 
gene. These core elements were flanked by the D M R 1 , the 
intergenic region, the H19 promoter and the H19 enhancer. 
The second construct contained the P3 promoter L U C linked 
with the intergenic region only (H). The third construct con-
sisted of the P3 promoter L U C fused with the H I 9 enhancer 
(A). The fourth construct consisted of the 5' D M R linked to 
the P3 promoter L U C (T). The fifth construct contained the 
P3 L U C flanked by the 5' D M R and the H19 enhancer (E). 
At gestational time E14.5 transgenic fetuses and their extra-
embryonic organs were collected. Primary embryonic fibro-
Table 1 
Luciferase activity 
Construct Placenta Yol 
+ 
+ 
+ 
+ 
+ 
c sack Cells 
PI 
+ 
+ 
— 
+ 
+ 
P10 
+ 
+ 
— 
+ 
+ 
5' DMR P3 LUC IGR H19 promoter H19 enhancer (O) + 
P3 LUC IGR (H) + 
P3 LUC H19 enhancer (A)* + 
5' DMR P3 LUC (T) + 
5' DMR P3 LUC H19 enhancer (E) + 
The transmission of different constructs in extraembryonic organs surrounding Fl transgenic embryos as well as fibroblast cultures produced from 
such embryos. The activity was assayed both in primary cultures (PI) and after 10 passages in culture (P10). RLU values < 100 were taken as 
negative. 
Transgene expression was detected in 50% of all placentae and yolk sacks and in most cases fibroblasts derived from the corresponding embryos 
indicated by (+). 
However this experiment (*) was repeated using three different transgenic lines containing the A construct. In two out of three cases the transgene 
did not express in the primary embryo fibroblasts. 
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blast cultures were established from the embryos and the lu-
ciferase activity determined in the cells as well as in samples 
from the corresponding placenta and yolk sack. The results 
are summarised in Table 1. It was found that all five con-
structs were transmitted to approximately 50% of the off-
spring from matings of transgenic males with non-transgenic 
females and were properly expressed in placenta and yolk 
sack. Moreover four of the constructs (O, H, T and E) were 
expressed in the fibroblast cultures whereas the P3 LUC H19 
enhancer construct (A) was only expressed in one out of three 
lines (Archy). The expression of O, H, T and E appeared to be 
stable and occurred at comparable levels both in the primary 
cultures and after ten passages. The frequent non-expression 
of construct A in embryonic fibroblasts is consistent with their 
derivation from predominantly mesodermal cell lineages, since 
the H19 enhancer has previously been shown to operate 
mostly (but not exclusively) in endodermal tissues [20,21,31] 
whereas the expression of e.g. construct H is consistent with 
the proposed role of the CCD as an enhancer in mesodermal 
tissues [19]. The unexpected finding that one out of three A 
lines (Archy) expressed the transgene raises the possibility that 
it was inserted in the vicinity of an enhancer element. 
This report, therefore, forms the basis for elucidating the 
molecular mechanism of glucocorticoid regulation of IGF II 
expression. Certainly, we believe that these studies should be 
conducted using constructs with endogenous enhancers which 
address the IGF II gene; firstly because of the relatively poor 
activity of enhancer-less constructs in transgenic mice [19] and 
Table 2 
The expression of transgenes in fibroblast cell cultures derived from Fl embryos 
Oat (O) 
Control 
10~9 M dexamethasone 
10~8 M dexamethasone 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Harry (H) 
Control 
10~9 M dexamethasone 
10~8 M dexamethasone 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Hamish (H) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
10~6 M hydrocortisone 
Holly (H) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Archy (A) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
10~6 M hydrocortisone 
Titus (T) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Elvis (E) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Line 2 (+) 
38 (100) 
133* (350) 
144* (379) 
202* (532) 
128* (337) 
Line 1 (+) 
46 (100) 
272* (591) 
104* (226) 
124* (269) 
88* (191) 
Line 2 (+) 
0.119 (100) 
0.119(100) 
0.131 (110) 
0.123 (103) 
Line 2 (+) 
0.860 (100) 
1.625* (188) 
1.400* (162) 
Line 3 (+) 
1.817 (100) 
1.799 (99) 
1.505 (83) 
1.789 (98) 
Line 3 (+) 
1.209 (100) 
1.672 (138) 
1.777 (147) n.d. 
Line 5 (+) 
2.538 (100) 
5.613* (221) 
4.864* (192) 
Line 4 ( - ) 
<0.1 
<0.1 
<0.1 
<0.1 
<0.1 
Line 2 (—) 
<0.1 
<0.1 
<0.1 
<0.1 
<0.1 
Line 1 ( - ) 
<0.1 
n.d. 
n.d. 
n.d. 
Line 3 ( - ) 
<0.1 
n.d. 
n.d. 
Line 5 (+) 
1.275 (100) 
1.515 (119) 
1.389 (109) 
1.512 (119) 
Line 4 ( - ) 
<0.1 
n.d. 
0.954 (132) 
Line 7 ( - ) 
<0.1 
n.d. 
n.d. 
Line 6 (+) 
48 (100) 
64 (133) 
179* (373) 
74* (154) 
58 (121) 
Line 5 (+) 
54 (100) 
139* (257) 
160* (296) 
172* (318) 
64(118) 
Line 3 (+) 
0.033 (100) 
0.025 (76) 
0.040 (121) 
0.046 (139) 
Line 5 (+) 
0.721 (100) 
1.148 (159) 
Line 6 (+) 
2.191 (100) 
8.265* (377) 
4.182* (198) 
*, significant difference between means, P< 0.025. 
n.d., not determined. 
Primary cultures were established from all embryos and initially screened for transgene expression. For each of the transgenes, one or two 
expressing and one non-expressing line was used. The cultures were exposed to different concentrations of glucocorticoids for 24 h whereafter 
the cells were harvested and subjected to luciferase activity as described in Section 2. 
To facilitate comparison of the data, in each case experimental values were converted to percentage of controls (figures within brackets). 
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Table 3 
The expression of transgenes in fibroblast cell cultures derived from 
Fl embryos, subsequently transfected with an expression vector con-
taining the human glucocorticoid receptor gene 
Hamish (H) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
10~6 M hydrocortisone 
Holly (H) 
Control 
10-7 M dexamethasone 
10~6 hydrocortisone 
Archy (A) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
10-6 M hydrocortisone 
Titus (T) 
Control 
10~7 M dexamethasone 
10~7 M hydrocortisone 
Elvis (E) 
Control 
10~7 M dexamethasone 
10-7 M hydrocortisone 
Line 2 (+) 
0.036 (100) 
0.046 (128) 
0.041 (114) 
0.037 (103) 
Line 2 (+) 
0.457 (100) 
0.665 (146) 
0.269 (58) 
Line 3 (+) 
0.180 (100) 
0.272 (151) 
0.269 (149) 
0.278 (154) 
Line 3 (+) 
1.138 (100) 
1.965* (173) 
1.560 (137) 
Line 5 (+) 
0.358 (100) 
1.982* (554) 
1.804* (504) 
Line 3 (+) 
0.017 (100) 
0.026 (153) 
0.200(118) 
0.019(112) 
Line 5 (+) 
0.193 (100) 
0.172 (89) 
0.151 (78) 
0.199 (103) 
Line 5 (+) 
0.536 
1.199* (224) 
0.865* (161) 
Line 6 (+) 
0.601 (100) 
1.705* (282) 
(0.986* (164) 
The cultures were exposed to different concentrations of glucocorti-
coids for 24 h whereafter the cells were harvested and subjected to 
luciferase activity as described in Section 2. 
To facilitate comparison of the data, in each case experimental values 
were converted to percentage of controls (figures within brackets). 
*, significant difference between means, P< 0.025. 
secondly because previous experiments using enhancer-less 
constructs in transient transfection assays were uninformative 
(Caricasole and Ward, unpublished observations). 
Fibroblasts containing constructs O, H, T and E and also 
the one line expressing the A construct were used to examine 
the effect of exogenously added glucocorticoids on this pro-
moter. The results are summarised in Table 2. It was found 
that both hydrocortisone and dexamethasone exerted a signif-
icant stimulatory effect on cells derived from mice carrying the 
O and E and in two out of three lines the H transgene. By 
contrast cells harbouring the T and in some cases the H trans-
gene did not increase their expression after exposure to any of 
the glucocorticoids. The single A line which expressed the 
transgene did not respond to glucocorticoid exposure. This 
is consistent with the notion that in this case the transgene 
has fallen under the control of an enhancer element at the 
insertion site. To exclude the possibility that these differences 
in response to exogenous glucocorticoids were due to lack of 
endogenous expression of the glucocorticoid receptor, the 
non-responsive cell lines were transfected with a vector con-
taining the human glucocorticoid receptor. The results of dex-
amethasone or glucocorticoid addition to the transfected cell 
lines are shown in Table 3. With one exception (Titus exposed 
to dexamethasone) the addition of endogenous glucocorticoid 
receptor expression did not result in a significantly increased 
glucocorticoid induced expression of the transgene. In the case 
of the Holly line, the exogenous receptor abrogates glucocor-
ticoid stimulation of transgene expression and we suggest this 
might be due to a dose dependent effect on receptor concen-
tration specific to this transgene insertion site. Taken together 
our data indicate that steroid hormones indeed enhance the 
usage of the insulin like growth factor II P3 promoter if some 
other control elements are present. 
It was initially believed that dexamethasone or hydrocorti-
sone down-regulates the IGF II expression in rodents by bind-
ing to the glucocorticoid receptor and that the glucocorticoid 
surge may be responsible for the postnatal decline in IGF II 
expression in rodents [10,11]. Furthermore, a similar postnatal 
decline in expression occurs in many of the transgenic mice 
from which cell lines were derived for use in this study [19]. 
However, even though some putative glucocorticoid respon-
sive elements have been identified in the rodent IGF II gene, 
their functional role remains to be characterised [10] and 
moreover none of these putative glucocorticoid receptor bind-
ing elements were part of our construct. The hormone recep-
tor complex binds to a conserved element in the regulatory 
region of the target gene. Such glucocorticoid receptor respon-
sive elements (GREs) are extremely well conserved and can 
either be up-regulating or down-regulating depending on oth-
er nuclear factors [32]. Recently it has been reported that an 
increase in circulating glucocorticoid levels leads to decreased 
IGF II transcript levels in adult mink liver [12], the opposite 
situation has been reported after long term treatment expo-
sure to glucocorticoids [13] or in pigs treated with dexametha-
sone [33]. In different species IGF II gene promoters are dif-
ferently used and in the case of higher mammals, such 
promoters are part of the developmental control machinery 
[15,18,34,35]. Consequently it is plausible that the IGF II gene 
promoters in different species might respond differently to 
glucocorticoid exposure. It should also be noted that our 
study was restricted to embryonic fibroblasts and the response 
of the IGF II P3 promoter to glucocorticoids might vary in 
other cell types. Although no putative GRE box has been 
traced in the murine IGF II P3 promoter, the binding site 
could be diverged from the consensus, alternatively this region 
might contain some motif that binds some factor which is 
synthesised in response to the steroid exposure. The other 
regulatory elements used in this study, and most particularly 
the CCD, have not been fully sequenced. It is therefore an 
alternative possibility that the action of glucocorticoids is in-
direct the up-regulation of IGF II P3 being effected by inter-
mediate gene products. Binding of these putative intermedia-
ries could be targeted to the enhancing elements rather than 
the actual P3 promoter. However, binding to the P3 region 
seems most likely since this is the only regulatory element 
present in all of the glucocorticoid responsive transgene con-
structs. 
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